SCHEMBL5135329

SCHEMBL5135329

CCCCN(Cc1ccc(OC)cc1)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
MAPT P10636 2/20 0.41
ATP4A P20648 3/20 0.41
ATP4B P51164 3/20 0.41
C5AR1 P21730 1/20 0.41
GLA P06280 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
GAA P10253 2/20 0.39
TSHR P16473 2/20 0.39
CNR2 P34972 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BCHE P06276 3/20 0.39
TSPO P30536 2/20 0.39
HPGD P15428 1/20 0.39
DRD2 P14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135871 0.95 ATP4A (0.44) TP53MAPTATP4AATP4BC5AR1
SCHEMBL5137368 0.94 TP53 (0.46) TP53MAPTC5AR1GLAALDH1A1
SCHEMBL5137164 0.94 C5AR1 (0.44) TP53MAPTATP4AATP4BC5AR1
SCHEMBL5134950 0.94 C5AR1 (0.45) MAPTATP4AATP4BC5AR1ALDH1A1
SCHEMBL5135937 0.93 ATP4A (0.49) MAPTATP4AATP4BDRD2DRD3
SCHEMBL5136000 0.93 ATP4A (0.42) MAPTATP4AATP4BC5AR1ALDH1A1
SCHEMBL5136763 0.93 KDM4E (0.43) ATP4AATP4BC5AR1ALDH1A1KDM4E
SCHEMBL5135824 0.93 C5AR1 (0.44) MAPTATP4AATP4BC5AR1ALDH1A1
SCHEMBL5136524 0.93 C5AR1 (0.46) MAPTC5AR1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5135885 0.92 MAPT (0.45) MAPTATP4AATP4BC5AR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed